Enjoy complimentary customisation on priority with our Enterprise License!
The global nontuberculous mycobacterial (NTM) infections market size is estimated to grow by USD 4.33 billion at a CAGR of 5.66% between 2023 and 2028.
As awareness among healthcare professionals and the broad public about nontuberculous mycobacterial infections rises, there is a parallel increase in the number of diagnosed cases. This heightened awareness leads to earlier detection and intervention, which has a positive impact on patient outcomes, thereby propelling the demand for effective treatments for NTM infections. Health education campaigns and awareness programs play a vital role in disseminating information about NTM infections, their risk factors, symptoms, and the significance of timely diagnosis and treatment. Moreover, several programs contribute to the awareness of NTM infections. One notable initiative is the NTM Info and Research organization, which focuses on providing information, resources, and support to individuals affected by NTM infections. Thus, such awareness programs will drive the growth of the market during the forecast period.
Technavio has segmented the market into Distribution Channel, Product, and Geography
It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historic data from 2018-2022, besides analyzing the current market scenario.
To learn more about this report, Download Report Sample
The market share growth by the hospital pharmacies segment will be significant during the forecast period. Hospital pharmacies serve as essential mediators in the distribution of pharmaceutical drugs, including antibiotics and other medications utilized to treat NTM infections. Hospital pharmacies work closely with suppliers and pharmaceutical companies to procure the required NTM infection-related drugs. Hospital pharmacies keep records of the medications that are dispensed to each patient. This assists in tracking the patient's treatment progress and ensures accountability.
Get a glance at the market contribution of various segments Download PDF Sample
The hospital pharmacies segment was valued at USD 4.97 billion in 2018. Furthermore, hospital pharmacies contribute to patient education, offering guidance on the need for medication adherence and potential drug interactions. The comfort of getting specified medications within the hospital/healthcare setting improves patient compliance with the treatment regimen, which is important for the effective management of NTM infections. Thus, such factors will drive the growth of the hospital pharmacies segment, which will drive the growth of the nontuberculous mycobacterial (NTM) infections market during the forecast period.
Clarithromycin, a macrolide antibiotic, is adored for its ability to inhibit bacterial protein synthesis, making it very effective in treating NTM infections. Clarithromycin exhibits a wide spectrum of activity against different NTM strains, making it a versatile choice in the treatment of these infections. Clinical guidelines usually recommend Clarithromycin as part of combination therapy for NTM infections, further driving its adoption in the healthcare industry. Moreover, with the rising prevalence of NTM infections globally, particularly among immunocompromised individuals, the demand for effective antibiotics like Clarithromycin is on the pitch. Therefore, such factors will fuel the growth of the Clarithromycin segment of the nontuberculous mycobacterial infections market during the forecast period.
The Azithromycin product type segment plays a vital role in the treatment of NTM infections owing to its effectiveness in treating mycobacterial infections. Azithromycin, a macrolide antibiotic, has shown efficacy against various strains of NTM, making it the best choice in the pharmaceutical arsenal for combating these infections. Azithromycin is available in different formulations, including oral tablets and suspensions, which provide convenient administration and lead to better patient compliance. Clinical guidelines often recommend Azithromycin as part of a combination therapy for NTM infections. Thus, such factors will drive the growth of the Azithromycin segment of the NTM infections nontuberculous mycobacterial infections market during the forecast period.
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 40% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. The rising prevalence of NTM infections in North America, particularly among individuals with underlying respiratory conditions or compromised immune systems, is a significant driver. North America brags a refined healthcare infrastructure with state-of-the-art diagnostic abilities and a well-established pharmaceutical industry. The availability of state-of-the-art diagnostic tools and the powerful capacity for clinical research contribute to the identification and understanding of NTM infections, facilitating the development and adoption of novel therapies.
In addition, the region's robust R&D ecosystem plays a key role in driving innovation in NTM treatments. Furthermore, pharmaceutical companies and educational institutions are actively employed in clinical trials, researching new drug candidates, combination therapies, and accurate medicine procedures to handle the challenges posed by NTM infections. Thus, such factors will drive the growth of the nontuberculous mycobacterial (NTM) infections market in North America during the forecast period.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 17 market companies, including:
Astellas Pharma Inc.: The company offers nontuberculous mycobacterial infection drug namely ASTAGRAF XL.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges.
The growing prevalence of NTM globally is the key factor driving market growth. According to the National Institutes of Health (NIH), from 2006 to 2021, the majority of NTM infections in individuals with non-CF bronchiectasis was expected to be around 10% worldwide, with considerable regional differences. The most prevalent subspecies was MAC, which was followed by Mycobacterium simiae and Mycobacterium gordonae. NTM infections are an emerging public health problem across the globe. Furthermore, the factors contributing to the rising prevalence of NTM infections include heightened awareness of these infections, improved diagnostic techniques, and an expanding population of immunocompromised individuals.
Moreover, as the prevalence of NTM infections continues to escalate worldwide, there is a growing demand for effective diagnostic tools and therapeutic interventions. In addition, pharmaceutical companies are actively employed in R&D to address this demand, leading to the introduction of new drugs and treatment modalities. This heightened focus on NTM infections, driven by their increasing prevalence, is expected to drive the growth of the global nontuberculous mycobacterial infections market during the forecast period.
The growing adoption of precision medicine for the treatment of NTM infections is the primary trend shaping market growth. Advances in genomic technologies allow a more exhaustive understanding of the genetic makeup of NTM strains. This knowledge facilitates the identification of specific molecular targets for drug development, allowing the creation of more effective and tailored therapies. Precision medicine enables healthcare providers to develop personalized treatment plans based on the individual patient's genetic profile and the characteristics of the infecting NTM strain.
Furthermore, collaborations between pharmaceutical companies, research institutions, and precision medicine-focused organizations are aimed at developing innovative therapies that align with the principles of precision medicine. Consequently, the introduction of precision medicine into the treatment of NTM infections will propel the growth of the market during the forecast period.
The heterogeneity of NTM strains is a challenge that affects market growth. NTM comprises a diverse group of mycobacteria species, each with unique characteristics, including varying antimicrobial susceptibilities. This heterogeneity complicates treatment approaches in several ways. Firstly, the diverse nature of NTM strains requires tailored treatment regimens, as different species may respond differently to the same antibiotics. This complexity inhibits the development of standardized, one-size-fits-all treatment protocols, making it challenging for healthcare providers to guide and prescribe effective therapies.
Also, the variability in clinical presentations and disease progression among patients infected with different NTM strains adds another layer of complexity. Tailoring the treatment based on the specific NTM strain and individual patient needs becomes crucial for achieving optimal outcomes, but heterogeneity impedes the establishment of standardized guidelines. Hence, the heterogeneity of NTM strains will impede the growth of the market during the forecast period.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Nontuberculous Mycobacterial Infections Market Customer Landscape
The nontuberculous mycobacterial infections market report forecasts market growth by revenue at global, regional & country levels and analyzes the latest trends and growth opportunities from 2018 to 2028.
Nontuberculous Mycobacterial Infections Market Scope |
|
Report Coverage |
Details |
Page number |
177 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 5.66% |
Market growth 2024-2028 |
USD 4.33 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
5.25 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 40% |
Key countries |
US, UK, Germany, Japan, and China |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Abbott Laboratories, Astellas Pharma Inc., Cipla Ltd., Dr Reddys Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Hikma Pharmaceuticals Plc, Insmed Inc., Johnson and Johnson, Lupin Ltd., Merck and Co. Inc., Pace Biotech, Pfizer Inc., QIAGEN NV, Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Lifesciences Ltd. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Distribution Channel
7 Market Segmentation by Product
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.